Abdominal Pain News and Research RSS Feed - Abdominal Pain News and Research

Abdominal pain is traditionally described by its chronicity (acute or chronic), its progression over time, its nature (sharp, dull, colicky), its distribution (by various methods, such as abdominal quadrant (left upper quadrant, left lower quadrant, right upper quadrant, right lower quadrant) or other methods that divide the abdomen into nine sections), and by characterization of the factors that make it worse, or alleviate it.
Phase 2 IMAGO trial of SHP625 fails to meet primary endpoints in pediatric patients with ALGS

Phase 2 IMAGO trial of SHP625 fails to meet primary endpoints in pediatric patients with ALGS

Shire plc today announced that the 13-week Phase 2 IMAGO trial of its investigational compound SHP625 (LUM001) did not meet the primary or secondary endpoints in the study of 20 pediatric patients with Alagille syndrome (ALGS), a rare, life-threatening genetic disorder that presents with chronic cholestasis (accumulation of bile acids in the liver) and severe pruritus (itching). [More]
Rhythm, Actavis announce initiation of relamorelin Phase 2b trial for treatment of diabetic gastroparesis

Rhythm, Actavis announce initiation of relamorelin Phase 2b trial for treatment of diabetic gastroparesis

Rhythm, a biopharmaceutical company, and Actavis plc, a leading global pharmaceutical company, announced today the initiation of a Phase 2b clinical trial assessing the efficacy and safety of relamorelin (RM-131), Rhythm's ghrelin agonist, for the treatment of gastroparesis in patients with type 1 and type 2 diabetes. [More]
Study examines new Ebola Prediction Score

Study examines new Ebola Prediction Score

Abdominal pain, fever and unexplained bleeding - which are commonly believed to indicate infection with the Ebola virus -- are not significantly predictive of the disease, according to the results of a study examining a new Ebola Prediction Score published online Friday in Annals of Emergency Medicine ("Derivation and Internal Validation of the Ebola Prediction Score for Risk Stratification of Patients with Suspected Ebola Virus Disease"). [More]
Rhode Island Hospital physician comes up with new diagnostic tool for Ebola virus

Rhode Island Hospital physician comes up with new diagnostic tool for Ebola virus

Adam C. Levine, M.D., an emergency medicine physician at Rhode Island Hospital and The Miriam Hospital who treated Ebola-infected patients in Liberia last year, used his field experience to create a tool to determine the likelihood that patients presenting with Ebola symptoms will actually carry the virus. [More]
Clinical trial uses personalized cellular therapy to treat GVHD complication of bone marrow transplant

Clinical trial uses personalized cellular therapy to treat GVHD complication of bone marrow transplant

An innovative clinical trial using the science of "personalized" cellular therapy has begun enrolling children and adults suffering from graft-versus-host-disease (GVHD), a life-threatening complication of bone marrow transplantation in which donor immune lymphocytes attack the organs of the bone marrow transplant recipient. [More]
International travelers bring multidrug-resistant shigellosis to the US

International travelers bring multidrug-resistant shigellosis to the US

International travelers are bringing a multidrug-resistant intestinal illness to the United States and spreading it to others who have not traveled, according to a report released today by the Centers for Disease Control and Prevention (CDC). [More]
MOVANTIK (naloxegol) now available in U.S. for treatment of OIC in adult patients with non-cancer pain

MOVANTIK (naloxegol) now available in U.S. for treatment of OIC in adult patients with non-cancer pain

Nektar Therapeutics reported that partner AstraZeneca announced today that MOVANTIK (naloxegol) has launched in the United States. On September 16, 2014, the US Food and Drug Administration (FDA) approved MOVANTIK as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain. [More]
Ultrasound safer than other imaging modalities for imaging female pelvis, say OB/GYN experts

Ultrasound safer than other imaging modalities for imaging female pelvis, say OB/GYN experts

Ultrasound technology has evolved dramatically in recent years. A group of noted obstetricians and gynecologists maintain that ultrasound is more cost-effective and safer than other imaging modalities for imaging the female pelvis and should be the first imaging modality used for patients with pelvic symptoms. [More]
Penn State surgeon provides guidelines for diagnosis, management of endometriosis

Penn State surgeon provides guidelines for diagnosis, management of endometriosis

Endometriosis is difficult to diagnose, with women often being told for years that they are experiencing their 'normal period.' According to the Endometriosis Foundation of America, it affects one in ten women. [More]
Fecal microbiota transplantation more successful for treating Clostridium difficile infections

Fecal microbiota transplantation more successful for treating Clostridium difficile infections

Distasteful though it sounds, the transplantation of fecal matter is more successful for treating Clostridium difficile infections than previously thought. [More]
Researchers develop noninvasive method to detect kidney cancer early

Researchers develop noninvasive method to detect kidney cancer early

If kidney cancer is diagnosed early — before it spreads — 80 percent of patients survive. However, finding it early has been among the disease's greatest challenges. [More]
Daiichi Sankyo signs co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol)

Daiichi Sankyo signs co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol)

Daiichi Sankyo, Inc. today announced a co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol) in the US, in line with the Daiichi Sankyo strategy to expand its US portfolio through strategic alliances, in addition to internal R&D and acquisitions. [More]
FDA approves CHOLBAM (cholic acid) for treatment of bile acid synthesis disorders

FDA approves CHOLBAM (cholic acid) for treatment of bile acid synthesis disorders

Asklepion Pharmaceuticals, LLC. today announced that the U.S. Food and Drug Administration (FDA) approved CHOLBAM (cholic acid) as a once-daily treatment for cholic acid deficiency in bile acid synthesis disorders due to single enzyme defects. [More]
Astute Medical hails launch of collaborative global initiative to prevent deaths from AKI by 2025

Astute Medical hails launch of collaborative global initiative to prevent deaths from AKI by 2025

Astute Medical, Inc. today hailed the launch of a collaborative global initiative calling for the elimination of preventable deaths from acute kidney injury (AKI) by 2025. The Company cited the publication of a new Commission from The Lancet and the International Society of Nephrology, along with the release of results from the 0by25 AKI "Global Snapshot" study, as key steps forward in the effort to reduce the global burden of AKI. [More]
Study: Cancer drug may help reduce bleeding in HHT patients

Study: Cancer drug may help reduce bleeding in HHT patients

A cancer drug that helps keep tumors from growing blood vessels may help patients with a rare genetic condition in which malformed vessels increase their risk for bleeding and anemia. [More]
Results of pacritinib Phase 2 study in myelofibrosis patients published in journal 'Blood'

Results of pacritinib Phase 2 study in myelofibrosis patients published in journal 'Blood'

CTI BioPharma Corp. today announced that results of a Phase 2 study of pacritinib, in patients with myelofibrosis were published in the journal Blood. Pacritinib is a next-generation oral JAK2/FLT3 multikinase inhibitor currently in Phase 3 development in the PERSIST program. [More]
Peanut consumption in infancy prevents allergy in kids who are at high-risk for developing peanut allergy

Peanut consumption in infancy prevents allergy in kids who are at high-risk for developing peanut allergy

A new study reported today in the New England Journal of Medicine demonstrates that consumption of a peanut-containing snack by infants who are at high-risk for developing peanut allergy prevents the subsequent development of allergy. [More]
Tillotts Pharma announces results of new survey in UC, introduces UCandME toolbox at ECCO 2015

Tillotts Pharma announces results of new survey in UC, introduces UCandME toolbox at ECCO 2015

Tillotts Pharma announced today results from a new European survey that revealed more than 9 out of 10 people with ulcerative colitis (UC) have low to medium adherence to their medication, putting them at five times greater risk of relapse. [More]
Two diagnostic tests can help identify children who require surgical treatment for appendicitis

Two diagnostic tests can help identify children who require surgical treatment for appendicitis

Data from two standard diagnostic tests commonly obtained in children evaluated for abdominal pain--when combined--can improve the ability of emergency department physicians and pediatric surgeons to identify those patients who should be sent to the operating room for prompt removal of an inflamed appendix; those who may be admitted for observation; and those who may safely be discharged home, according to a new study published online as an "article in press" in the Journal of the American College of Surgeons. [More]
Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis plc, during its Investor Meeting in New York, today provided a detailed look into its standalone global pharmaceutical development pipeline that supports the Company's long-term organic growth. The Company provided details regarding key development programs, including clinical data, development milestones and an overview of potential market opportunities, as well as an updated look at Actavis' world-class generics pipeline, which continues to hold an industry-leading position in First-to-File opportunities in the U.S. [More]
Advertisement